OAIM
OAIM
OneAscent International Equity ETF
The OneAscent International Equity fund takes an innovative approach to international investing. The strategy combines the OneAscent Elevate Screening Process along with the investment team’s Life Cycle Investment approach. The team conducts extensive fundamental analysis to arrive at a concentrated portfolio of companies it believes could be more likely to outperform.
Key Uniques:
A Focus on Societal Impact
With the help of the OneAscent Elevate Screening methodology, the investment team seeks out those companies around the world that are providing goods or services that advance the flourishing of society. A deep dive into a company’s business model, stakeholder policies, and overall community impact helps to eliminate those companies that do not share our values and thereby allowing the team to focus on companies in which our clients can be proud to own.
Unique Fundamental Framework
The investment team believes companies go through a natural corporate “Life Cycle” and understanding where a company lies along that spectrum is central to the fundamental investment process. With the help of quantitative tools, the team is able to segregate the investment universe into life cycle stages and attempt to more accurately identifying a company’s real asset growth and return on invested capital. Using this lens, the team applies a rigorous fundamental analysis process to help identify those companies more likely to create ongoing shareholder value.
Experienced Global Investment Team
The investment team is led by a portfolio manager with decades of investment experience in global equity markets. The team manages multiple, high conviction portfolio using the same rigorous bottom-up investment process.
Fund Details | As of 02/21/2025 |
---|---|
Ticker | OAIM |
Primary Exchange | NYSE Arca |
CUSIP | 90470L436 |
Inception Date | 9/15/22 |
Net Assets | $135,420,986.46 |
Shares Outstanding | 4,150,000.00 |
Gross Expense Ratio | 0.99% |
Net Expense Ratio | 0.95% |
Distribution Frequency | Annually |
Fund Price | As of 02/21/2025 |
---|---|
NAV | $32.99 |
Market Price | $32.65 |
30-day Median Bid/Ask Spread | 0.30% |
Premium Discount | $0.02 |
Historical Premium/Discount
Year 2024 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
---|---|---|---|---|---|
Days at premium | 184 | 57 | 48 | 35 | 43 |
Days at discount | 57 | 3 | 12 | 26 | 14 |
The Premium/Discount shows the difference between the daily market price of the Fund’s shares and the Fund’s net asset value (“NAV”). Market price data reflects the official closing price. This data is provided for information purposes only and is not intended for trading purposes. Past performance does not guarantee future results.
Performance
As of 12/31/2024
Trailing Returns
3 Month | YTD | 1 Year | Since Inception | |
OneAscent International Equity ETF (Price) | -4.42% | 8.19% | 8.19% | 13.93% |
OneAscent International Equity ETF (NAV) | -4.53% | 8.09% | 8.09% | 13.90% |
MSCI ACWI ex USA Index | -7.60% | 5.54% | 5.54% | 11.12% |
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. For performance current to the most recent month end, please call 1-800-222-8274.
The total Fund operating expense is 0.99%. The Fund’s adviser contractually has agreed to waive its management fee and/or reimburse expenses so that total annual Fund operating expenses, do not exceed 0.95% through December 31, 2025.
Source: Morningstar Direct
Elevate Stories
When a company elevates every single person and every square inch, they create stories worth sharing.
Below are examples from this fund.
Olympus Corp.
Gastrointestinal, pancreatic, and liver diseases are the major causes of global mortality, resulting in 8 million deaths worldwide each year.1
Olympus’s TXI™ Technology increases the visibility of lesions and polyps that could turn cancerous by revolutionizing image quality in endoscopic screening.
Webuild SPA
More than 2 billion people do not have safe drinking water available, leading to 1,000 child deaths per day.2
Webuild SPA is a global leader in water treatment and waste management. Its water projects consist of reverse osmosis desalination and thermal desalination plants having served over 20 million people.
Vinci SA
Morocco currently faces an energy shortage due to its heavy reliance on imported fossil fuels, importing around 90% of its energy needs, leaving it vulnerable to price fluctuations and supply disruptions.3
In Morocco, Vinci Construction is building the Abdelmoumen pumped storage energy transfer station. Compensating for the intermittency of renewable energy sources, this structure stores electrical energy in hydraulic form when demand is low, and releases it when demand increases, smoothing out supply disruption and limiting price volatility.
Jeol Ltd
Materials, technology, and healthcare have become more complex and diverse.4
Not only does Jeol produce some of the most advanced electron microscopes on the market, but they also provide regular training sessions and seminars on electron microscopes, spectrometers, nuclear magnetic resonance, and biochemical automatic analyzers.
Enel
Traditional power plants emit pollutants such as sulfur dioxide, nitrogen oxides, carbon dioxide, and mercury causing cancer, respiratory problems, cardiovascular problems.5
Enel has built the first floating photovoltaic plant, using part of a large service reservoir at a hydroelectric power plant that has been in operation since the late 1960s. The solar and hydropower hybrid plant creates clean, sustainable, efficient electricity with no impact to the landscape as the plant floats on the already existing artificial reservoir
Top 10 Holdings as of 02/21/2025 | Weight |
---|---|
BBH SWEEP VEHICLE | 8.14% |
TAIWAN SEMIC-ADR | 3.58% |
KBC GROUP | 3.51% |
DBS GROUP HLDGS | 3.47% |
CRH PLC | 3.25% |
BANGKOK BANK-F | 2.74% |
SIEMENS AG-REG | 2.69% |
NOMURA RESEARCH | 2.63% |
MITSUB ELEC CORP | 2.59% |
WISE PLC - A | 2.49% |
View all holdings (csv) |
As a percent of net assets. Portfolio Holdings are subject to change and should not be considered investment advice. Current and future portfolio holdings are subject to risk.
Investors should carefully consider the investment objectives, risks, and charges and expenses of the fund before investing. The prospectus contains this and other information about the fund, and it should be read carefully before investing. Investors may obtain a copy of the prospectus by calling 1-800-222-8274 or clicking the link above. The fund is distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with OneAscent Investment Solutions, LLC.
Important Risk Information:
Exchange-traded funds involve risk including the possible loss of principal. Past performance does not guarantee future results.
The Adviser invests in securities only if they meet both the Fund's investment and values-based screening requirements, and as such, the returns may be lower than if the Adviser made decisions based solely on investment considerations.
The Fund faces numerous market trading risks, including the potential lack of an active market for Fund sharers, losses from trading in secondary markets, and periods of high volatility and disruption in the creation/redemption process of the Fund. These factors may lead to the Fund's shares trading at a premium or discount to NAV.
High conviction is a style of active management that is expressed through portfolio construction. Without deploying a consistent high-conviction approach over time, it is hard for any manager to beat the benchmark or passive fund equivalent for their target sector.
The fund contains international securities that may provide the opportunity for greater return but also have special risks associated with foreign investing including fluctuations in currency, government regulation, differences in accounting standards and liquidity.
1Olympus Corp: Mohammad Javad Zahedi, Sara Shafieipour, Mohammad Mahdi, et al. “Mortality Trends of Gastrointestinal, Liver, and Pancreaticobiliary Diseases: A Hospital-Based Prospective Study in the Southeast of Iran.” NIH.
2Source: https://www.theguardian.com/environment/2024/oct/16/global-water-crisis-food-production-at-risk
3Source: https://www.trade.gov/country-commercial-guides/morocco-energy
4Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC1121189/#:~:text=Across%20all%20disciplines%2C%20at%20all,care%20is%20becoming%20more%20complex; https://www.wipo.int/en/web/economics/w/blogs/which-are-the-world-s-most-complex-capabilities
5Source: https://www.epa.gov/power-sector/power-plants-and-neighboring-communities#:~:text=description%20and%20download-,Overview,Hg)%2C%20and%20other%20pollutants